Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase - Institut Pasteur Accéder directement au contenu
Article Dans Une Revue Proceedings of the National Academy of Sciences of the United States of America Année : 2014

Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase

Olaf Schneewind
  • Fonction : Auteur correspondant
  • PersonId : 1105861

Connectez-vous pour contacter l'auteur

Résumé

Methicillin-resistant Staphylococcus aureus (MRSA) is the most frequent cause of hospital-acquired infection, which manifests as surgical site infections, bacteremia, and sepsis. Due to drug-resistance, prophylaxis of MRSA infection with antibiotics frequently fails or incites nosocomial diseases such as Clostridium difficile infection. Sortase A is a transpeptidase that anchors surface proteins in the envelope of S. aureus, and sortase mutants are unable to cause bacteremia or sepsis in mice. Here we used virtual screening and optimization of inhibitor structure to identify 3-(4-pyridinyl)-6-(2-sodiumsulfonatephenyl)[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole and related compounds, which block sortase activity in vitro and in vivo. Sortase inhibitors do not affect in vitro staphylococcal growth yet protect mice against lethal S. aureus bacteremia. Thus, sortase inhibitors may be useful as antiinfective therapy to prevent hospital-acquired S. aureus infection in high-risk patients without the side effects of antibiotics.

Dates et versions

pasteur-03262305 , version 1 (16-06-2021)

Identifiants

Citer

Jie Zhang, Hongchuan Liu, Kongkai Zhu, Shouzhe Gong, Shaynoor Dramsi, et al.. Antiinfective therapy with a small molecule inhibitor of Staphylococcus aureus sortase. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111 (37), pp.13517-13522. ⟨10.1073/pnas.1408601111⟩. ⟨pasteur-03262305⟩

Collections

PASTEUR CNRS
6 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More